UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 27

Sortiert nach

Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia

Clinical cancer research, 2012-04, Vol.18 (7), p.2099-2107

2012

Link zum Volltext

Verfügbarkeit prüfen

Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells

Molecular pharmacology, 2015-06, Vol.87 (6), p.1006-1012

2015

Link zum Volltext

Verfügbarkeit prüfen

Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx

Molecular cancer research, 2017-08, Vol.15 (8), p.1096-1105

2017

Link zum Volltext

Verfügbarkeit prüfen

Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy

Discovery medicine, 2012-01, Vol.13 (68), p.19

2012

Link zum Volltext

Verfügbarkeit prüfen

Racial Disparities in the Association Between Variants on 8q24 and Prostate Cancer: A Systematic Review and Meta‐Analysis

The oncologist (Dayton, Ohio), 2012-03, Vol.17 (3), p.312-320

2012

Link zum Volltext

Verfügbarkeit prüfen

Bcl-2 Family of Proteins as Therapeutic Targets in Genitourinary Neoplasms

Clinical genitourinary cancer, 2013-03, Vol.11 (1), p.10-19

2013

Link zum Volltext

Verfügbarkeit prüfen

Prostate cancer genomic signature offers prognostic value

Cancer biology & therapy, 2010-12, Vol.10 (11), p.1079-1080

2010

Link zum Volltext

Verfügbarkeit prüfen

Multi-institutional Study of Outcomes After Pediatric Heart Transplantation: Candidate Gene Polymorphism Analysis of ABCC2

The journal of pediatric pharmacology and therapeutics, 2014-01, Vol.19 (1), p.16-24

2014

Link zum Volltext

Verfügbarkeit prüfen

Dual targeting of the androgen receptor and hypoxia-inducible factor-1α pathways to synergistically inhibit castrate-resistant prostate cancer

Journal of clinical oncology, 2015-03, Vol.33 (7_suppl), p.270-270

2015

Link zum Volltext

Verfügbarkeit prüfen

Androgen receptor and HIF-1α interaction in prostate cancer

Journal of clinical oncology, 2012-02, Vol.30 (5_suppl), p.197-197

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2206: Molecular interaction of HIF-1α and the androgen receptor in prostate cancer

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.2206-2206

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract B29: A meta-analysis of racial disparities in the association between 8q24 and prostate cancer risk

Cancer research (Chicago, Ill.), 2012-02, Vol.72 (4_Supplement), p.B29-B29

2012

Link zum Volltext

Verfügbarkeit prüfen

Activity of oral VT-464, a selective CYP17-lyase inhibitor, in the LNCaP prostate cancer xenograft

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.4671-4671

2012

Link zum Volltext

Verfügbarkeit prüfen

Association between variants on 8q24 and prostate cancer: A review and meta-analysis

Journal of clinical oncology, 2012-02, Vol.30 (5_suppl), p.28-28

2012

Link zum Volltext

Verfügbarkeit prüfen

Activity of VT-464, a selective CYP17 lyase inhibitor, in the LNCaP prostate cancer xenograft model

Journal of clinical oncology, 2012-02, Vol.30 (5_suppl), p.64-64

2012

Link zum Volltext

Verfügbarkeit prüfen

TRANSPORTER POLYMORPHISMS AFFECT NORMAL PHYSIOLOGY, DISEASES, AND PHARMACOTHERAPY

Discovery medicine, 2012-01, Vol.13 (68), p.19-34

2012

Link zum Volltext

Verfügbarkeit prüfen

Light‐Induced Content Release from Plasmon‐Resonant Liposomes

Advanced materials (Weinheim), 2009-06, Vol.21 (22), p.2334-2338

2009

Link zum Volltext

Verfügbarkeit prüfen

Development of a new permeability assay using low‐efflux MDCKII cells

Journal of pharmaceutical sciences, 2011-11, Vol.100 (11), p.4974-4985

2011

Link zum Volltext

Verfügbarkeit prüfen

Preliminary Evaluation of a Prescription Opioid Misuse Prevention Program Among Rural Middle School Students

Journal of community health, 2020-12, Vol.45 (6), p.1139-1148

2020

Link zum Volltext

Verfügbarkeit prüfen

Refining the In Vitro and In Vivo Critical Parameters for P-Glycoprotein, [I]/IC50 and [I2]/IC50, That Allow for the Exclusion of Drug Candidates from Clinical Digoxin Interaction Studies

Molecular pharmaceutics, 2010-04, Vol.7 (2), p.398-411

2010

Link zum Volltext

Verfügbarkeit prüfen

Leveraging Technology to Facilitate Teachers’ Use of a Targeted Classroom Intervention: Evaluation of the Daily Report Card.Online (DRC.O) System

School mental health, 2019-12, Vol.11 (4), p.665-677

2019

Link zum Volltext

Verfügbarkeit prüfen

N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a “chemical knock-out equivalent” to assess the impact of efflux transporters on oral drug absorption in the rat

Journal of pharmaceutical sciences, 2009-12, Vol.98 (12), p.4914-4927

2009

Link zum Volltext

Verfügbarkeit prüfen

PHARMACOKINETICS, PHARMACODYNAMICS AND DRUG METABOLISM: N-(3,4-Dimethoxyphenethyl)-4-(6,7-Dimethoxy-3,4-Dihydroisoquinolin-2[1H]-yl)-6,7-Dimethoxyquinazolin-2-Amine (CP-100,356) as a Chemical Knock-out Equivalent to Assess the impact of Efflux Transporters on Oral Drug Absorption in the Rat

Journal of pharmaceutical sciences, 2009, Vol.98 (12), p.4914-4927

2009

Link zum Volltext

Verfügbarkeit prüfen

Refining the In Vitro and In Vivo Critical Parameters for P-Glycoprotein, [I]/IC 50 and [I 2 ]/IC 50 , That Allow for the Exclusion of Drug Candidates from Clinical Digoxin Interaction Studies

Molecular pharmaceutics, 2010-04, Vol.7 (2), p.398-411

2010

Link zum Volltext

Verfügbarkeit prüfen

Moving Target Defense for Space Systems

2021 IEEE Space Computing Conference (SCC), 2021, p.60-71

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(26)
Tagungsberichte
(1)

Sprache

Englisch
(27)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia

Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells

Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx

Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy

Racial Disparities in the Association Between Variants on 8q24 and Prostate Cancer: A Systematic Review and Meta‐Analysis

Bcl-2 Family of Proteins as Therapeutic Targets in Genitourinary Neoplasms

Prostate cancer genomic signature offers prognostic value

Multi-institutional Study of Outcomes After Pediatric Heart Transplantation: Candidate Gene Polymorphism Analysis of ABCC2

Dual targeting of the androgen receptor and hypoxia-inducible factor-1α pathways to synergistically inhibit castrate-resistant prostate cancer

Androgen receptor and HIF-1α interaction in prostate cancer

Abstract 2206: Molecular interaction of HIF-1α and the androgen receptor in prostate cancer

Abstract B29: A meta-analysis of racial disparities in the association between 8q24 and prostate cancer risk

Activity of oral VT-464, a selective CYP17-lyase inhibitor, in the LNCaP prostate cancer xenograft

Association between variants on 8q24 and prostate cancer: A review and meta-analysis

Activity of VT-464, a selective CYP17 lyase inhibitor, in the LNCaP prostate cancer xenograft model

TRANSPORTER POLYMORPHISMS AFFECT NORMAL PHYSIOLOGY, DISEASES, AND PHARMACOTHERAPY

Light‐Induced Content Release from Plasmon‐Resonant Liposomes

Development of a new permeability assay using low‐efflux MDCKII cells

Preliminary Evaluation of a Prescription Opioid Misuse Prevention Program Among Rural Middle School Students

Refining the In Vitro and In Vivo Critical Parameters for P-Glycoprotein, [I]/IC50 and [I2]/IC50, That Allow for the Exclusion of Drug Candidates from Clinical Digoxin Interaction Studies

Leveraging Technology to Facilitate Teachers’ Use of a Targeted Classroom Intervention: Evaluation of the Daily Report Card.Online (DRC.O) System

N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a “chemical knock-out equivalent” to assess the impact of efflux transporters on oral drug absorption in the rat

PHARMACOKINETICS, PHARMACODYNAMICS AND DRUG METABOLISM: N-(3,4-Dimethoxyphenethyl)-4-(6,7-Dimethoxy-3,4-Dihydroisoquinolin-2[1H]-yl)-6,7-Dimethoxyquinazolin-2-Amine (CP-100,356) as a Chemical Knock-out Equivalent to Assess the impact of Efflux Transporters on Oral Drug Absorption in the Rat

Refining the In Vitro and In Vivo Critical Parameters for P-Glycoprotein, [I]/IC 50 and [I 2 ]/IC 50 , That Allow for the Exclusion of Drug Candidates from Clinical Digoxin Interaction Studies

Moving Target Defense for Space Systems

Suchergebnisse filtern